GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Price-to-Free-Cash-Flow

Aptevo Therapeutics (Aptevo Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Apr. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-04-27), Aptevo Therapeutics's share price is $0.7061. Aptevo Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-37.84. Hence, Aptevo Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Aptevo Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

APVO's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.52
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Aptevo Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-11.89. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-37.84.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 52.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 46.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 27.70% per year.

During the past 11 years, Aptevo Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 52.00% per year. The lowest was 3.40% per year. And the median was 25.40% per year.


Aptevo Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Aptevo Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics Price-to-Free-Cash-Flow Chart

Aptevo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptevo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aptevo Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Aptevo Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptevo Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's Price-to-Free-Cash-Flow falls into.



Aptevo Therapeutics Price-to-Free-Cash-Flow Calculation

Aptevo Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.7061/-37.838
=N/A

Aptevo Therapeutics's Share Price of today is $0.7061.
Aptevo Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.84.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Aptevo Therapeutics  (NAS:APVO) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Aptevo Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptevo Therapeutics (Aptevo Therapeutics) Business Description

Traded in Other Exchanges
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Executives
Daphne Taylor officer: SVP, CFO 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon officer: See Remarks APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux officer: Senior VP, Operations 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi director 400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White director, officer: President and CEO 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi director 2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell officer: SVP, GC and Corporate Affairs 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman officer: SVP, Commercial Operations 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross officer: See Remarks 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121

Aptevo Therapeutics (Aptevo Therapeutics) Headlines

From GuruFocus

Aptevo to Present at Bio-Europe Conference

By ACCESSWIRE 11-01-2023